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ABSTRACT
Two groups of New Zealand white rabbits were injected with
homogenate3 from Tumorous-head (Tuh) and Wild-type (WT) Drosophila
melanogaster.

A third group was used as a saline injected control.

Blood collected in both acute and chronic studies was subjected to
various hematological and post mortem studies.
The Tuh injected group showed a five-fold increase in thrombocytes (blood platelets) over the controls and a four-fold increase
over the wild-type group.

Reduced clotting times were noted from

acute to chronic studies in both tumorous and wild-type studies;

however, the magnitude of change between the two groups was insignificant.

Investigations involving electrophoretic banding pat-

terns, differential blood cell counts, and comparative hematocrits,
provided less significant results.
The author concludes that the reduced clotting times reported
in tumorous-head injected rabbits represent a decrease in bleeding
time.

This was caused by the more effective plugging of the damaged

vessel by the increased number of platelets.
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INTRODUCTION
The term hemophilia is loosely applied to several hereditary
deficiencies of coagulation, all of which cause bleeding tendencies
hardly distinguishable from one another.

Regar'dless of the precise

type of hemophilia, transfusion of normal fresh plasma or of the
appropriate purified protein clotting factor into the hemophilic
person usually relieves his bleeding tendency for a few days (1).
The present study involves the relative effects of several antigens
on the hemostatic mechanism and, therefore, warrants an expanded
discussion of hemostasis.
Wnen the walls of blood vessels are severed, the subsequent
blood loss is reduced by a sequence of reactions known collectively
as hemostasis.

There are three major facets of hemostasis:

vascu-

lar spasm, the formation of platelet plugs, and plasma coagulation
(1).

The nervous

reflexes are presumably initiated by pain impul-

ses originating from the traumatized vessel or from nearby tissues.
The reflex signal travels first to the spinal cord, then back through
the sympathetic nerves causing spasms which extend several centimeters in either direction from the point of rupture.
lasts between a few seconds to a few minutes.

The reaction

Most spasms probably

result from local myogenic contractions of vessels initiated by direct damage to the vascular wall (1).
1

Compared to our knowledge

2

about the coagulation mechanism, 1ittle is known about the role of
the vasculature in hemostasis (2).

Zucker (3), Chen &Tsai (4), and

Bernan & Fulton (5) believed that the rate of blood flow through a
vessel influences the local concentration of precoagulants in the
Increased flow rate would reduce the local precoagulant

blood.

concentration whereas decreased flow rate would further enhance this
concentration.

Vasocontriction with consequent decreased blood flow

would, therefore, be expected to be beneficial to the hemostatic
process.

Zucker {3,6) maintained that vasoconstriction involves not

only the injured vessel but also others in the immediate vicinity,
apparently because of the platelets' rele?se of serotonin, a vasoconstrictor substance.

Although vasoconstriction is inadequate to

effect hemostasis, it has been suggested that the vasoconstrictor
effects of serotonin may contribute to the process.
Williams (2) reported that the activation of the Hageman Factor
{Coagulation Factor XII) may possibly contribute to hemostasis by
initiating the reactions of blood coagulation and by the production
of peptides which are able to increase capillary permeability and
smooth muscle contraction.

Platelets may also release substances

that increase capillary permeability {7).

Increased capillary per-

meability may improve hemostasis by increasing the viscosity of blood
within the vessels (8).

Active vasoconstriction plays no role in

hemostasis in nonmuscular vessels such as capillaries and some venules.

Blood flow in these vessels may be retarded by local tissue

pressure, by adhesion of endothelial or connective tissue elements,

3

or by arteriolar constriction (3,4,5).
According to Williams (2), the vascular endothelium provides
an inert surface for the reactions of blood coagulation and platelet
aggregation.

The smoothness of the endothelium, along with presence

of its monomolecular layer of negatively charged proteins, prevent
contact activation of the intrinsic clotting system by repelling
platelets and other clotting factors.

Damage to the endothelial

surface causes loss of smoothness and negative electrical charge.
This is believed to help activate Factor XII, thus initiating the
intrinsic pathway of clotting.

Sawyer (9) observed that electrical

currents within and across the vessel wall may help to initiate
irreversible clumping of the platelets, followed by their adhesion
to the injury site.
Astrup and Buluk (10) and Kirk (11) indicated that the endothelium of blood vessels is rich in thromboplastic activity.
appears to be tissue thromboplastin (Coagulation Factor III).

This
Tis-

sue Factor III reacts with Factor VII and calcium to form a complex
to initiate reactions to the extrinsic pathway of blood coagulation
and leads to rapid formation of thrombin (figure 2).

Thombin may

then also effect platelet aggregation, or fibrin formation, and thus
accelerate the reactions of hemostasis.
The intima of blood vessels contain significant quantities of
plasminogen activator which may be released at the injury site and
act as a protective mechanism against excessive local fibrin formation (2).

4

Guyton (1) describes the formation of the platelet plug as the
second hemostasis event.

This is the action by the platelets to

close the vessel's trauma site.

An understanding of this phenomenon

-

warrants an explanation of the nature of platelets themselves.
Platelets, or thrombocytes, are minute round or oval discs about
2 microns in diameter and are derived from the cytoplasm of megakaryocytes, large immature cells in the bone marrow (1).

After matura-

tion, these cells fragment into cytoplasmic clumps which are released
into the peripheral circulation as functional platelets (12).

Each

megakaryocyte is capable of producing 3,000 to 4,000 platelets (13),
but the number produced and released in the bone marrow is regulated
by the number already in circulation (14).

In man, the normal plasma

concentration of platelets ranges from 150,000 to 450,000 per cubic
millimeter while their life span is approximately ten days, with a
half-life of three days (12).
White (15) suggests that a platelet can be divided into three
structural areas or zones, each zone being involved in a specific
function.

These are the peripheral zones, the sol-gel zone, and the

organelle zone.
The peripheral zone is involved in adhesion and aggregation.
It separates the platelet from its surrounding medium and is composed
of an exterior coat, a membrane, and submembrane filaments.

The

exterior coat is an amorphous substance, rich in mucopolysaccharides and glycoprotein.

Clottino factors identical to those present

in the plasma are present.

~

The membrane just below the exterior coat
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is the source of platelet Factor 3 (PF3), a phospholipid which
becomes available on the surface of the platelet during irreversible
aggregation.

PF3 interacts with some clotting factors in the intrin-

sic pathway to produce fibrin.
The sol-gel zone provides support for cell structure and mechanisms for cell contraction.

The peripheral zone and the sol-zone

share submembrane filaments.

The submembrane filaments, along with

microtubules and microfilaments in the sol-gel zone, help to support
the shape of unaltered platelets and, in response to stimuli, help in
the extension and stabilization of pseudopod formation.

They also

participate in the contractile process during irreversible aggregation and retraction.

The microfilaments are the source of the con-

tractile protein, thrombosthenin.
The organelle zone, which consists of organelles randomly distributed throughout the cytoplasm is concerned with respiratory,
excretory and production functions, as well as storage and release of
energy.

It also regulates the platelet's chemical and physiologic

response to stimuli.
Williams {2) observed that platelets undergo three changes during hemostasis:

adhesion {aggregation), contraction, and secretion

{releasing reaction).

Adhesion is an independent facet in platelet

physiology, because adhesion can occur without contraction.

Secre-

tion is dependent on the contractile system of platelets; hence, it
cannot occur alone.
secretion.

Contraction can develop up to a point without

The contractile mechanism in platelets consists of the
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fusion of centrally clumped organelles and the selective release of
several endogenous components that aid in hemostasis.
Platelets respond to vascular trauma by drastic reorganization
of both their internal and surface structure (15).

When they come in

contact with a wettable surface, such as the subendothelial collagen
fibers in the vascular wall, the following changes occur:

they begin

to swell (1); the submembrane filaments and microtubules form a constrictive band around the platelet organelles; the centrally located
organelles fuse (15); they assume irregular forms with numerous
irradiating processes protruding from their surfaces (1); the exterior coat acquires adhesive qualities causing the platelets to adhere
to the collagen fibers at the damaged vessel site.
release of certain chemical constituents occurs.

Subsequently,
These constituents

are usually bound to the membrane surfaces and may participate in
clotting by providing acceleratory influences.

Several of these

activities have been designated as platelet factors 1 to 4 (2).
Platelet factor 1 is plasma coagulation factor V adsorbed by the
platelets (16).

Platelet factor 2 is a protein which accelerates

the clotting of fibrinogen by thrombin, aggregates platelets from
platelet-rich plasma further potentiating the piatelet aggregating
effect of ADP (17), and counteracts the inhibitory effects of plasma
antithrombin III on a thrombin-induced

fibrinogen~fibrin

reaction.

Platelet factor 3 or 4 are both influenced by aggregation {18,19,
20).

Platelet factor 3, a lipoprotein component of platelet membrane,

becomes available to coagulant enzymes and cofactors of plasma
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following platelet aggregation or platelet trauma (21 ,22,23).

The

active component is the phospholipid moiety bound to both membranes
and granules which accelerates plasma clotting, probably by acting as
a surface catalyst (23).

The lipid membrane is more readily exposed

for participation in clotting (24).

Activation occurs because the

soluble enzymes are provided a surface on which to act, thus, having
the effect of concentrating the enzymes in a localized area, leading
to faster reaction rates (25).

Phospholipids accelerate blood coagu-

lation by participating in the reactions involving factor VIII and
those involving factor V.

Little activity can develop even when the

release reaction does not occur (26,27).

Platelet factor 4 is a gly-

coprotein (28) released from platelets following platelet aggregating by ADP, thrombin, or epinephrine (29-31).

It shortens the

thrombin clotting time in the presence of heparin (29-32), potentiates ADP-induced aggregation in vitro, precipitates fibrinogen, nonenzymatically clots soluble fibrin monomer complexes (24), and neutralizes certain fibrinogen breakdown products (antithrombin VI) (33).
Platelets also contain intracellular fibrinogen (34-37) which appear
not to be derived from plasma fibrinogen and may be synthesized in
the megakarycyte (37).

As indicated previously, some other constitu-

ents released by platelets are serotonin, adenosine triphosphate
(ATP), and large quantities of adenosine diphosphate (ADP) (15).
The ADP aids in activating nearby platelets causing them to adhere
to the originally activated platelets.

Therefore, at any vascular

trauma site the exposed subendothial collagen elicits a continuous
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cycle activating successively increasing numbers of platelets accumu lating in the formation of the hemostatic platelet plug.

This is a

fairly loose plug; however, the blocking of blood loss is usually
successful.
formed.

During the process of blood coagulation, thrombin is

It further alters the platelets to irreversible aggregation,

thus forming a tight and unyielding plug.

In performing the usual

coagulation tests one generally deals with the concentrations of factors present in plasma at normal or less than normal concentrations.
Under certain conditions the platelet concentration may be important
as well.

Excessive platelet concentrations is a condition called

thrombocytosis.

Depending on the effectiveness of hemostatic or

thromboplastic functions of this condition, a reduced bleeding time
or clotting time may possibly result.

Transitory thrombocytosis may

result from the mobilization of extravascular platelet pools, for
example, following epinephrine administration (38) or vigorous
exercise (39).

All other forms of thrombocytosis apparently are

the result of accelerated platelet production.

Preliminary thrombo-

kinetic data would suggest that this may result from two different
mechanisms (Table 1).

In individuals with reactive or secondary

thrombocytosis, the platelet count is directly col'related with the
megakaryocyte mass and is inversely correlated with the mean megakaryocyte volume.

This is the result of regulatory processes that nor-

mally reduce the stimulus to nuclear
let count rises (40,41).

endoredupl~cation

as the plate-

A direct and linear relationship between

platelet turnover rate and total megakaryocyte mass has been

9

Table 1
Thrombocytosis (2)
A.

B.

Primary Jautonomous)
1.

Essential thrombocythemia

2.

Other myeloproliferative disorders

Secondary (Y'eactive}
1.

Chronic inflammatory disorders

2.

Acute inflammatory disorders

3.

Acute hemorrhage

4.

Iron deficiency

5.

Hemolytic anemia

6.

Malignant disease

7.

Postoperative

8.

Response to drugs

9.

Response to exercise

10
demonstrated {40,41}.

The factors leading to accelerated platelet

production in the various disorders associated with reactive thrombocytosis are almost totally obscure.

The principal importance of

this disorder is the recognition of its benign nature and its differentiation from autonomous thrombocytosis.
In autonomous thrombocytosis, platelet production apparently is
unresponsive to normal regulatory processes; and the platelet count
does not correlate with the megakaryocyte volume as seen in Table 2
{40}.

The uecrease in megakaryocyte size normally resulting from

an increase in the circulating platelet mass is absent.

Autonomous

thrombocytosis has been likened to neoplastic proliferation of other
hematopoietic elements {42).
The megakaryocyte-thrombocyte system has been shown to respond
to thrmbocytopenia and thrombocytosis by respectively increasing and
decreasing platelet production {43,44,45}.
shown to be humorally mediated {46,47).

These responses have been

While almost nothing is

established about thrombopoietin, it is known to affect both the number of magekaryocytes found within the marrow and their proliferative
behavior {47).

With stimulation, there is an increase in the rate of

maturation of the megakarocyte size resulting from an increase in
the number of mitosis within the individual cells, and possibly an
increase in the size of thrombocytes appearing in circulation.

With

suppression, megakarocytes are smaller and contain a decreased number
of nuclei.

The changes affect the number of platelets produced per

megakaryocyte.

An inverse relationship is also normally found between
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Table 2
Differentiation of Reactive and Autonomous Thrombocytosis

Reactive
Thrombocytosis
(secondary)

Autonomous
Thrombocytosis
(primary)

THROMBOKINETIC FEATURES
Total megakaryocyte
mass
Megakaryocyte number
Megakaryocyte volume

Greatly
Slightly increased
increased
Increased
Increased
Increased
Decreased

Platelet turnover or
production rate

Increased

Increased

Total platelet mass

Increased

Increased

Platelet survival

Normal

Normal to
slightly
increased

Thromboembolism and hemorrhage

Uncommon

Common

Duration

Often transitory

Usually~

Splenomegaly

Absent*

Platelet count
Bleeding time

Usually> 3
400,000/mm
Usually norma 1

Usually>
1 ,000,000/mm 3
Often
prolonged

Platelet morphology and
function

Usually normal

Often abnormal

Leukocyte count

Usually normal

Increased in
90% of cases

CLINICAL AND LABORATORY FEATURES

*Unless as the result of the underlying disorder.
Thrombokinetic data from Harker (40).

persistent
80% of cases
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the number of thrombocytes in circulation and in the size of megakaryocytes within the marrow (40).

In the thrombocytosis accompanying

inflammatory states and iron deficiency, however, there is dissociation between increased megakaryocyte number and the number of thrombocytes produced per megakaryocyte.

At the present time, it is impos-

sible to say whether megakaryocyte stimulation is mediated by one or
more sti mulating factors.
Studies of cyclic variations in the platelet count in normal
individuals and in individuals with cyclic thrombocytopenia and tidal
platelet disgenesis, suggest that the control of thrombopoiesis
involves a negative "feedback" mechanism that contains a time delay.
A result of the time lag may magnify perturbations of either a positive or negative nature, resulting in an oscillation of platelet production.

More than one humoral regulation, or a combination of nega-

tive and positive feedback regulatory process, may be involved (4g).
Accelerated thrombopoiesis commonly is associated with accelerated erythroopoiesis.

Thus, increased platelet numbers are present

in subjects with various hemolytic anemia (49), following acute blood
loss ( 50,51,52) , and in some subjects with secondary polycythemia
associated with renal tumors

~ 53).

The association of thrombocyto-

sis with various neoplasms has been recognized for many years (52).
Platelet counts in excess of 400,000/mm 3 may be found in a large proportion of individuals with neoplasms, in as many as 40 percent of
cases in one study (54).

The persistence of post-splenectomy throm-

bocytosis in anemic subjects has been found.

Despite the evidence
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that thrombopoietin and erythropoietin are different substances (55),
these findings suggest that there is some interrelationship between
erythropoietic and thrombopoieti: control mechanisms (56).
Several interdependent coagulation factors enter into reactions
that initiate clotting (see Table 3).

The deficiency of any factor

may result in an abnormal hemostatic response.

Any increase in fac-

tor concentration, in association with changes in the rate of blood
flow, may lead to thrombus formation (2).
In 1904, Morawitz presented the classical Theory of Blood
Coagulation.

He postulated that:

a) prothrombin, calcium, and fibrinogen were present in
circulating blood.

b blood remained fluid in the absence of thromboplastic
factor which he called Thomboplastin .. or "Thrombokinase."
11

c) thromboplastic factor resulted from tissue injury or
platelet disintegration.
d) thromboplastic factor could convert prothrombin into
thrombin with subsequent fibrin formation. (12)
Many research workers in the field of blood coagulation refer
to Morawitz•s thromboplastic factor or thromboplastin as prothrombin
activator.

Unfortunately, the detailed mechanisms of prothrombin

activator formation are still not clear.

However, there is much

better understanding of the mechanisms of prothrombin conversion to
thrombin and action of thrombin to cause fibrin thread formation.
Guyton (1) indicated that this causes the polymerization of fibrinogen
molecules into fibrin threads within 10 to 15 seconds.

The rate

intrinsic and extrinsic

IV

v

Calcium

Proaccelerin

VII

Early, middle,
1ate, i ntri ns i c
and extrinsic

III

Tissue
thromboplastin

Precursor of
serum prothrombin conversion
accelerator
(ProSPCA)

Late, intrinsic
and extrinsic

II

Prothrombin

Trace

9-11.5

7 or less

170-400

Plasma
Concentration
(mg/100 ml plasma)

f"liddle, intrinsic 5 (or less)

~~iddle,

Early, extrinsic

Late, i ntri ns i c
and extrinsic

I

Roman
Numeral

Fibrinogen

Conmon Name

Stage of
Participation
in 13lood
Coagulation
Electrophoretic

Between x
and (3
globulin

Between f3
and y
globulin

70,000; 99,000;
180,000; 390,000;
350,000 (bovine)

62,850 (bovine)

x2
globulin

339,700 (human)
340,000 (bovine)
501 ,800 (horse)

Molecular Weight

Between 13
and y
globulin

~1igration

The Proteins of Blood Coagulation (57)

Table 3

__.
..p.

e,
intrinsic and
extrinsic

Early,
intrinsic

Early,
intrinsic

Late, i ntri nsic, and
extrinsic

IX

X

XI

XII

XIII

Antihemophilic
factor (AHF)

Christmas
factor

Stuart factor

Plasma thromboplastin antecedent (PTA)

Hageman factor

Fibrin stabilizing factor

( FSF)

Middle,
intrinsic

VIII

Comnon Name

r~i ddl

Middle,
intrinsic

Roman
Numeral

Stage of
Participation
in Blood
Coagulation

Trace

Trace

Trace

0.5-1

0.5-1

1 (or less)

Plasma
Concentration
(mg/100 ml plasma)

Table 3 (continued)

globulin

f32

8-y
globulin
region

S-y
globulin
region

globulin

X

globulin

X2

globulin

a2

- - --

Electrophoretic
Migration

350,000 (human)

82,000 (bovine)
20,000 (human)

85,000-87,000
(bovine); 54,00056,000 (bovine)

90,000 (bovine)

1-2 million (bovine
and human); 180,000
(human and pig)

Molecular Weight

~

U"1
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limiting factor in causing blood coagulation is usually the formation
of prothrombin activator and not the subsequent reactions beyond that
point.

The reactions in figure 1 are a modified illustration of

Morawitz's postulate demonstrating the conversion of prothrombin
to thrombin under the influence of prothrombin activator and calcium
ions.
Prothrombin
Extrinsic ~
or

Ca

Intrinsic~

Prothrombin
Activator

Thrombin

Fibrinogen-------- Fibrin Monomer

Fibrin stabilizing factor
Fibrin Threads
Figure 1.

r~orawitz's

classical theory of blood

coagulation
As previously indicated,the rate of formation of thrombin
from prothrombin is almost directly proportional to the quantity of
prothrombin activator available.

This in turn is approximately pro-

portional to the degree of trauma to the vessel wall or blood.

In

turn, the rapidity of the clotting process is proportional to the
quantity of thrombin formed.
Guyton (1) further described the action of thrombin on fibrinogen

1.7

to form a molecule of fibrin monomer.

He noted that as several

fibrin monomer molecules polymerize within seconds into long fibrin
threads, they form the reticulum of the clot.

In the early stages of

this polymerization, the fibrin monomer molecules attach to one
by loose hydrogen and hydrophobic bonds, forming weak polymer

a~other

chains.

However, immediately thereafter, another plasma globulin

factor, the fibrin stabilizing factor, acts as an enzyme to cause
covalent bonding between the fibrin monomer molecules and also
between the adjaGent polymer chains.

Williams (2) noted this factor

as catalyzing the formation of peptide bonds between glutamic acid
and lysine groups in adjacent molecules of fibrin monomers in the
clot.
the

This adds tremendously to the three dimensional meshwork of
threads and yields a mechanically strong, hemostatically

f~brin

e fective c1ot.
Two types of prothrombin activator resulting from two avenues
of coagulation have been postulated (1):
1.

2.

Tissue extract called the extrinsic pathway
Plasma thromboplastin called the intrinsic pathway

The terms "intrinsic .. and extrinsic refer to clotting inside and
11

outside the

vasculat~

11

system, respectively.

With respect to effective

rates, the intrinsic system is relatively slower than the extrinsic
system.

In either case, the final common pathway is the conversion

of prothrombin to thrombin.

In both path\'lays a series of plasma pro-

teins, especially beta globulins, play major roles.

These along with

the factors previously discussed are called blood clotting factors (1).
One of the more recent schemes devised to diagram the
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coagulation process was the cascade or waterfall sequence illustrated
by Davie, Ratnoff (58), and MacFarlane (59).

This is based on the

theory that the blood coagulation process is primarily a series of
enzyme reactions.

These reactions are subdivided into three

stages (figure 2).
Erslev and Gabuzda (60) describe the first phase of the intrinsic system as the surface activation of Factors XII and XI.

The

conversion of Factor XII to XIIa ("a" denotes activated form) seems
to require prior complex formation with Factor XI, which in turn
is c:.anged to XI a.

Factor XI a then triggers coagulation by acti vat-

ing IX to IXa, a potent pracoagulant.

A complex is then formed of

Factors IXa and VIII with platelet phospholipid.

The formation of the

uFactor VIII complex .. is accelerated by the presence of small quantities of thrombin.

This complex then converts Factor X to Xa, which

bv itself has "prothrombinase .. activity.

The rate of reaction, how-

e 'er, is markedly accelerated by the presence of Factor V and platelet phospholipid.
The extrinsic system short circuits the first stage of the
intrinsic system by directly activating Factor X through the formation of a complex between Factor VII and tissue thromboplastin, which
is composed of phospholipid and protein (60).
Calcium is required for most of the coagulation reactions, a
point of considerable laboratory importance.

In vitro, blood can be

prevented from clotting by reducing the calcium ion concentration
below the threshold level for the clotting, either by deionizing the
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calcium by reacting it with substances such as citrate ion or by pre cipitating the calcium with substances such as the oxalate iron, both
substances commonly used as anticoagulant in laboratory coagulation
testing (1).

However, it is virtually impossible for hypocalcemia

to be of sufficient magnitude in vivo to cause abnormal bleeding.
Whether activated forms of Factors V, VII, and VIII exist or whether
their activity is mediated solely through complex formation with phospholipid remains uncertain.

As previously indicated, the thrombin

formed as the end-product of this accelerating series of reactions,
in addition to forming fibrin monomer and activating Factor XIII!,
also engages in .. positive feedback .. by increasing platelet aggregation and promoting Factor VII complex formation.

Modulating influ-

ences on the negative side come from enzyme antagonists in the plasma.
The activated forms of the coagulation factors are cleared from the
circulation rapidly, which is also of considerable importance in
keeping the process of clot formation under physiologic control (60).
Most of the tests of the clotting mechanism depend on the
appearance of a fibrin clot in the test tube.

Quick (62) believed

that if he added calcium and a source of prothrombin activator to
oxalated plasma, prothrombin would be the rate limiting component
of the clotting reaction.

This test not only measures prothrombin

specificially, but also factors I, V, VII, and X as well (see figure
3).

The present investigation explores the hemostatic responses of
rabbits to antigens from Wild-type and Tumorous head strains of fruit

Calcium

Fibrin

Figure 3.

Stages of blood coagulation

All three stages of blood clotting and the fourth stage (lysis) may be occurring
continuously in minute amounts in the homeostasis of normal blood. The presence
of free plasmin in more than trace amounts is abnormal.
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flies.

A recent immunological investigation (63) produced results

which could provide additional insights in studies concerned with the
future treatment of hereditary deficiencies in coagulation.

That

investigation involved the intramuscular injection of New Zealand
White rabbits with emulsifications prepared from wild-type and
tumorous-head Drosophila melanogaster.

The Tumorous-head Drosophia

is a mutant strain of fruit fly in which homoetic tumors are produced
on the head region.

These tumors may take the shape of leg append-

ages or abdominal, or genital tissue.

The protocol of Weihe's (63)

research consisted of 5 injections at 10-aay intervals.

Following a

six-week resting period, blood was collected by ear-vein laceration.
During these collections, it was noted that the rabbits immunized
with the tumerous-head flies showed decreased bleeding times and
increased hemolysis in the serum relative to the rabbits immunized
with wild-type flies.
Necrotic tissue areas were observed at the injection sites in
both rabbit groups.

The group immunized against the wild-type anti-

gens possessed tissue that was diffuse and filled with a viscous, puslike substance at the injection sites.

The tumerous-head injected

group possessed more localized and indurated tissue at the injection
sites (63}.
This study involves the relative effectiveness of the clotting
mechanism in rabbits following intramuscular injections of homogenates from wild-type and tumourous-head Drosophila melanogaster
compared with the saline injected controls.

MATERIALS AND METHODS
New Zealand white rabbits having an average weight of 4 pounds
were used in both acute and chronic studies.

Each study was sub-

divided into 3 groups:
1.
2.
3.

Tumorous-head injected
Wild-Type injected
Saline (Control) injected

The following strains of Drosophila melanogaster were used in
this study:
1.
2.

a tumorous-head mutant strain obtained from Arizona
State University, and symbolized Tu-h (ASU)
laboratory wild-types, including Oregon R-C, Canton S,
Swedish C, and Urbana S, obtained from California
Institute of Technology and symbolized W-t.

Experimental cultures were maintained at 25°C in one-half pint milk
bottles on freshly prepared standard Drosophila medium containing cornmeal-agar-dried yeast -sucrose-molasses with propionic acid added as
a mold inhibitor (64).
The tumorous-head fly suspensions were obtained by emulsifying
100 male and 100 female flies in a tissue grinder containing 4 ml of
0.9% saline solution.
per injection.

Therefore, a dose of 200 Tu-h flies was used

Similarly, the wild-type suspensions were obtained

by emulsifying 25 male and 25 female flies from each of the four
strains of W-t Drosophila, totaling 200 flies per injection per rabbit, in the 4 ml saline solution.

The control group was injected

with 4 ml 0.9% saline solution per rabbit.
23

All dosages were
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administered by intramuscular injections at the biceps femoris.
Whole blood was collected from all rabbits 10 days after the
first injection for the acute study.

The chronic study consisted of

a series of 5 injections at 10-day intervals with blood collection
10 days after the final injection.

The blood was obtained by ear-

vein laceration and mixed with sodium oxalate in siliconized test
tubes.

Approximately 10 ml of each sample was immediately centri-

fuged at 14,900 g for 20 minutes at -5 to 5+°C for plasma separation
and isolation.

The remainder was used for various hematological

assays.
The following parameters were examined on all blood types:
1.
2.
3.
4.
5.
6.
7.

Hematocrit
Red blood cell count
White blood cell count
Platelet count
Hemoglobin determination
Prothrombin times (plasma)
Electrophoresis (plasma)
Hematocrit

Red blood cell volume percentages were obtained from hematocrit values.

They were determined by centrifuging blood in heparin-

ized capillary tubes and measuring the packed cell volumes on the
critocap chart.
Cell Counts
Red blood cell, white blood cell, and platelet counts were
done by coulter counter.

Cells were diluted with Isoton at 1:50,000

for RBc•s, 1:500 for wsc•s, and 1:3000 for platelets.

All counts
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were adjuste1 using the coulter counter coincidence correction chart.
Hemoglobin Determination
Hemoglebin concentrations were determined by hemoglobinometer
(Coulter Electronics} and expressed in grams percent.

The 1:50,000

cell dilution utilized in the red blood cell count was again employed
in this hemoglobin determination.
Prothrombin Time
Blood collection and plasma separation were accomplished as
previously described.

Plasma was promptly removed to another con-

tainer and stored prior to testing the same day.

Reagents used were

liquid activated raobit brain thromboplastin (prothrombin activator)
and 0.02M calcium chloride.
The experimental procedure followed for determination of prothrombin times was published by Dade (65}.

Equal quantities of

activated thromboplastin and 0.02M calcium chloride were mixed and
the resulting solution was pipetted in 0.2 ml aliquots into each of
the desired number of 13 x 100 mm chemically clean test tubes.

A

small amount of test plasma was warmed at 37°C for one minute, followed by forceful blowing of 0.1 ml of the test plamsa into the prewarmed activated thromboplastin-calcium chloride mixture.

A timer,

:alibrated in tenths of a second, was started simultaneously.
tube was quickly shaken and rotated so as to insure mixing.
appearance of the first fibrin web denoted the end point.

The
The
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Post-Mortem Inspection
All rabbits were sacrificed using sodium pentabarbital (Nembutal) and autopsies conducted following the above examinations.
objective of these studies was two-fold:

The

1) general inspection of

gross appearance of internal anatomy, and 2) general inspection of
gross appearance of the injection sites.
Special attention was given to organs concerned with the reticuloendothelial system--the liver and spleen.

However, there was

inspection of major organs of both thoracic and peritoneal cavities.
InJection sites were examined for the reported localized, indurated
necrosis versus the diffuse, viscous, purulent necrosis of the Tuh
and riT specimens, respectively {63).
Electrophoresis
Plasma samples were diluted in a 1:10 ratio with 0.9% physiological saline.

It was found that better banding resolutions could

be established with .02 ml plasma containing 70 mg/ml of protein
activity.
5.5~

Polyacrylamide gel electrophoresis was carried out on a

gel prepared from the following solutions mixed per 100 ml of

deionized water:

1) two parts solution I [14.0 grams acrylamide
(Aldrich) to 0.4 grams N,N 1--methylene-bisacrylamide (Isolab)],

2) one part solution II [tri-borate buffer as described later],
3) one part solution III [0.4 grams ammonium persulfate (J. T.
1 1
Baker)] by volume. Added to the solution was .01 ml of N,N,N ,N tetramethylethylenediamine.

The solution was placed in 75 ml x 5 m

ID x 8 mm O.D. electrophoresis tubes to polymerize.
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A Buchler tube gel electrophoretic system was used with gel
and chamber buffer composed of a tris-borate buffer.

The buffer was

composed of 2 20 boric acid, 4.31 g Tris (hydroxymethyl) aminomethane
and 0.37 g EDTA terrasodium salt per 100 ml of distilled H2o. The
chamber buffer was a 1:4 dilution of the stock gel buffer with a
final pH of 8.6.

One gram of ultrapure sucrose was added to the 20

ml gel solution to eliminate mixing when water is layered over the
surface.

One-tenth grams of ultrapure sucrose was dissolved in 1 ml

of plasma sample to facilitate layering on gel.

Bromophenol blue

was used as a marker to observe the migration on the sample.

Gels

were run at 30 milliamps for two hours at 25°C, and placed in 1%
Coomassie blue (BB G-250)--trichloroacetic acid solution overnight.
The required washing and destaining was done with 12.5% trichloroacetic acid, with changes performed periodically until the gel was
clear.
Statistical Analysis
The animals were grouped according to the type of injection
received, that is, the Control (saline), the Wild-Type (WT), or the
Tumorous head (Tuh) injected rabbits.

A study denotes the quantity

of injections prior to assay, that is, acute Study (one injection)
and chronic Study (five injections).

The mean values of cell counts,

prothrombin times, hernatocrits, and hemoglobin determination were
subjected to unpaired "T" tests {Appendix 1) to determine significant
changes between Groups (Control-WT-Tuh).

Likewise, within each Study,

analysis of variance was applied to determine significant changes in
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the following categories {66):
1)

Between Groups, that is, acute and chronic Control groups
(Category A)
versus acute and chronic Wild-Type groups
versus acute and Tumorous head groups.

2) Within Groups,

that is, acute Studies versus chronic
Studies.

3) Interactions,
(Category AB)

that is, acute Control versus chronic
Control-acute Wild-Type versus chronic
Wild Type-acute Tumorous head versus
chronic Tumorous head.

(Category B)

Following post marten inspections, tissue samples from the liver,
spleen, and injection site growths were provided for pathophysiologic
analysis (67 ) .

RESULTS
The results of the prothrombin times are summarized in Table 4
and figure 4.
studies.

Mean values (X) are taken from both acute and chronic

The prothrombin times were measured in nine rabbits from

each acute Study and eleven rabbits in each chronic Study.

The

analysis of variance revealed a significant decrease of 13.5% in the
Within Groups category with an overall acute mean value of 9.12 seconds compared to 7.89 seconds in the overall chronic study (Appendix
2) . There were no significant changes in the Interaction and Between
Group categories; however, significant time reductions were observed
from acute to chronic means in both WT and Tuh Groups as revealed by
tests (Table 5).
The results of the hematocrits are indicated in Table 6 and
figure 5.

Hematocrits were taken from nine rabbits in each acute

study and eleven rabbits in each chronic study.
changes were shown by analysis of variance.

No significant

Significant differences

were revealed between the chronic WT and chronic Tuh and between the
acute Control and acute WT as shown by T tests in Table 5.

However,

the 1.1 % decrease from acute Control to acute Wild Type was very
minimal.

Mean values tended to remain close to the 39.28% Grand Mean

of packed red blood cell volume.

It is interesting to note a 5.2%

increase in hematocrits from acute Tuh to the chronic Tuh (38.78 to
40.78%) in the Interactions category.
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Table 4
Maan Values of Prothrombin Times for Both Acute and Chronic Assays

~HRONIC

ACUTE
Animo ~

no.

I

r·~P~

CONTROL

1
2

-

3
4
5
6

TUMQROUS

HEAD

-

-

8.07

8.70

11.26

10.60

9.24

11.00

9.30

.

WIL~

CONTROL

1UN,eROUS

TYP

8.27

HEAD

I

7.60

9.91

8.30

8.40

9.04

8.23

8.85

9.13

9.02

8.68

8.50

9.20

9.22

8.33

8.35

8.82

8.50

8.60

7.55

8.25

6.97

7
8
9

8. 31

8.05

8.07

7. 31

7.09

7.48

8.31

8.28

8.23

8.18

7.74

7. 31

8.i4

8.80

9.26

7.70

6.90

7.93

10
11

9.38

9.10

8.33

7.44

8.00

6.98

10.10

9.91

10.84

7. 51

7.40

6.82

-X

8.99

9.27

9.10

8.16

8.18

7.70

.575

1. 20

1 .00

.745

.902

.641

.330

1. 41

1. 00

.556

.813

.411

s

52

-

9. 20
I

I

Mean values are recorded as time in seconds. T values showed significant reductions from acute to chronic means in both WT and Tuh
groups.
Analysis of variance 5howed significant decreases of the overall acute
mean to overall chronic mean.
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W-T

Control

Changes in mean prothrombin times for
Tuh, WT, and control animals in acute
and chronic studies.

Chronic

2.9033*(-)

17.8760*(-)

Hemoglobin
Concentration

Red Blood
Cells

- .0155 (+)

-7.0627*(+)

11

Each value represents the calculated "T" for the various groups (see Appendix 1). The* indicates significant changes at the .05 level. Each "T value is absolute. The (+/-) signs note
increases or decreases of mean values.
**T tests were also performed on acute versus chronic tumorous-head and on acute versus
chronic Wild-type injected animals for the prothrombin times. Both comparative studies
revealed significant reductions in the times.

-5.7026*(+}

. 2751 (-} - 1.8758*(+)

-.8457 (+)

te Blood
Cells

\~hi

14.5357*(+)

•

- .3766 (+)

- .5344 (+) -12.8621*(+)

.7917 (+)

Platelets

- .3671 (+)

-2.4207*(+)

1.4384 (-)

-5.4140*(+)

-8.7850*(+)

1 . 5514 (-)

1. 0988 (-) - 1.4660 (+)

- .0567 (+)

24.0388*(-) - 3.4338*(+)

9.9920*(-)

-1.3844 (+)

- .2302 (+)

-1.1734 (-)

2.0234+(-)

Hematocrit

1.8948*(-)

.3284 (-)

-.2856 (+)

-.6371 (+)

Prothrombin
Times**

Control vs. Control vs. Wild-Type vs. Control vs. Control vs. Wild-Type vs.
Wild Type Tumorous-head Tumorous-head Wild-Type Tumorous-head Tumorous-head

Acute

List of "T" Values for the Comparisons of Control and
Treatment Groups in Both Acute and Chronic Studies

Table 5

w
N
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Table 6
Mean Values of Hematocrits for Both Acute and Chronic Assays

Anima l
no.

ACUTE
'1~~-~

CONTROL

1

I

-

I

TUt.;\CROUS
HEAD

-

-

2

CHRONIC

-

I

WILD

CONTROL

-

42

-

40

TYPE

I

TUMOROUS
H ~EA D

40

40

38

40

3

40

36

40

39

38

41

4
5
6
7

41

40

40

41

41

40

40

39

37

40

40

42

39

37

40

36

35

38

42

39

40

41

38

43

8
9
10

40

40

40

38

38

38

40

40

42

39

39

40

40

38

35

38

41

45

11

37

38

35

40

37

40

39.88

38.55

38.77

39.45

38.63

40.63

1. 4

1.4

2.5

1. i

1. 8

2.1

2.0

2.0

6.2

2.9

3.3

4.3

-X

s

52

I

I

I

Mean values are recorded as cell percentage of whole blood. T value3
demonstrated a significant decrease between acute control and acute
Wild-Type and a significant increase from chronic Wild Type to chronic
Tumorous head. Analysis of variance showed no significant changes.
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Changes in mean hematocrits for Tuh, WT, and
control animals in acute and chronic studies.
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The results of the hemoglobin determination are shown in
Table 7 and figure 6.

Hemoglobin determinations were taken from six

rabbits in each acute study and nine rabbits in each chronic study.
There were significant changes in the Interactions category (Appendix
2).

These results showed a 12.0% decrease from the acute Controls

to the chronic Controls (11.25 gm % to 9.90 gm %); an 11.0% increase
from the acute WT to chronic WT (8.61 gm % to 9.63 gm %); and a 9.7%
increase from the acute Tuh to the chronic Tuh (9.82 gm % to 10.77 gm
~) .

The T tests showed significant decreases of 23.5% and 12.7% in

both acute WT and Tuh Groups, respectively, with respect to the Control.
The results of erythrocyte counts are illustrated in Table 8
and figure 7.

Erythrocyte counts were taken from six rabbits in

each acute study and nine rabbits in each chronic study.

The Within

Groups category showed a 36.0% elevation of the chronic study mean of
5.97 x 1o6; mm 3 compared to the acute mean of 4.39 x 10 6/mm 3 (Appendix
2).

All categories indicated significant changes as shown by T

tests (Table 5).

The acute assays showed a 30 and 16.1 %decrease in

the mean erythrocyte counts of Wild-type and Tuh groups, respectively,
as compared with the Control.

There were 20.5%more erythrocytes in

the acute Tuh than the acute WT.

Chronic assay values showed a 4.5%

decrease in WT and a 15.4% increase for the Tuh injected group as
compared with the Control, and a 20.8% increase for Tuh compared with
WT rabbits.
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Table 7
Mean Values of Hemoglobin Determination for Both
Acute and Chronic Assavs
-.-

~HRONIC

ACUTE
Anjrc;~ l

.

1
2
3
4

t'~~~

CONTROL

-

-

5
6

10.40

7

12.20

8

12.40

9

11.05

10
11

I

TUM~ROUS

HEA

-

-

-

-

7.50

8.70

7.40

-

9.20

15.40

10.40

-

12.30

9.40

12.10

9.16

8.00

9.30

8.75

9.20

-

flLD
YPE

CONTROL

-

-

-

EAD

-

-

I

~UEMQ.RQ: IS

I

7.70

11.50

11.10

10.90

10.60

10.50

9.80

9.70

11.00

14.00

6.90

11.05

10.40

8.90

12.10

12.45

10.55

8.30

10.20

9.10

9.10

9.00

6.80

9.10

10.00

8.60

10.10

8. 61

9.82

9.82

10.14

10.51

I

I

-

11.25

s

1.38

1. 75

1.23

1.47

2.16

2.01

1. 90

3.06

1. 52

2.17

4.66

4.02

52

I

Mean values are recorded as concentration in grams percent. T values
indicated significant decreases in both acute Wild Type and Tumorous
head with respect to the acute Control. Analysis of variance showed
significant changes in the Interactions category.
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Changes in mean hemoglobin concentrations for Tuh,
WT, and control animals in acute and chronic studies.
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Table 8
Mean Values of Erythrocyte Count of Both Acute and Chronic Assays

I

An~mol
10.

~HRONIC

ACUTE
WI~D

CONTROL

TUMOROUS

HEAD

TY E

I

CONTROL

-

-

-

-

-

-

-

-

-

-

1
2
3
4
5
6
7

5,500,000

3,340,000

5,160,000

3,680,000 5,520,000

8

IS ,459,000

3,520,000

TUMOROUS
HEAD_

WILD
I

TYPE

-

I

-

3,660,000 4,480,000 3,780,000
4,445,000 5,360,000 5,400,000
5,476,000 4,660,000 5,475,000

I

~,368,000

~,507,000
I

4,203,000 4,880.000 r·786.000
11 0 ,960 '000

3 '940 ,000 0$70,000

4,310,000 8,536,000 7,980,000
5,100,000 4,646,000 5,923,000

9

!4 '903 ,000

4,026,000

~,600,000

10
11

5,276,000

4,145,~00

6,540,000 5,356,000 4,996,000 6,503,000

r3 ,as3 ,ooo 2,990,000

-

5,193,000

3,616,833

s

769,413.0

431,115.0
1.8xlo 10

52

~,620,000

5,016,000

4,806,000~4,636,000
I

5.9xlo 10

I

~ '359 '166

5,368,444 5,126,000 6,192,555

727,305.8 2,177,031 1,335,657 2,108,572
11 1 . 8xl 011 4.4x1o 11
5.3xlo 10 4.7xlo

Mean values are recorded as erythrocytes per cubic millimeter of blood.
T values revealed significant decreases of both acute and chronic Wild
Type rabbits. In addition, T values demonstrated significant increases
of both acute and chronic Tumorous head, as compared to the respective
Wild Types and the chronic Tumorous head group and respect to the
Control. Analysis of variance showed a significant increase of overall
chronic mean with respect to overall acute mean.
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Changes in mean erythrocyte count for Tuh,
WT, and chronic studies.
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The results of the thrombocyte count are shown in Table 9 and
figure 8.
th~

Only chronic studies were performed using five rabbits in

Control groups, four rabbits in the WT groups, and six rabbits

in the Tuh groups.

Mean values and T tests (Table 5) indicate a

marked increase in thrombocytes in the Tuh Group.

A hyper-elevated

501.2 J increase of Tuh compared with the Control groups and a 432.2%
increase of Tuh compared with WT shows a thrombocytotic tendency.
Analysis of variance was not applied to this assay.
Table 10 and figure 9 show the results of leukocyte mean values.

Leukocyte counts were taken from six rabbits in the acute Study

and nine rabbits in the chronic Study.

No significant changes were

indicated by analysis of variance; however, a 19.4% leukocyte elevation can be seen from the overall acute mean to overall chronic
mean (Appendix 2).
5.

These changes were indicated by T tests in Table

They were a 15.2 increase for the acute Tuh Group compared with

acute Controls, a 30.5 J increase for the chronic Tuh compared with
chronic Controls, and a 30.5% increase for chronic Tuh compared with
chronic WT.
The results of the post-mortem inspections are summarized in
Tables 11 and 12.
The qualitative examination of the electrophoretic banding
resolutions revealed no major consistent visual differences between
the injected groups.
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Table 9
Mean Values of Thrombocyte Count for Both Acute and Chronic Assays

An~r;noi
o.

ACUTE

CHRONIC
~UEADRO S CONTROL

WI~D

C.ONTROL

TY E

WILD

I

TUMO!(OUS
HEAD

TYPE
I

1
2
3

-

-

-

-

-

-

-

-

-

4

-

-

5

-

-

6
7

-

-

i

I

781,720
I

98,760
204,040

122 '180

-

346,720
521 ,060

64,840

93,720

360,060

88,800

114,760

575,900

66,060

154,120

557,060

-X

104,500

121,195

523,770

s

57,528.7 25,042.0 160,301

8
9
10
11

52

~309549600 '6 2 7103566

2 564671485

Mean values are recorded as thrombocytes per cubic millimeter of blood.
T values showed significant increases of chronic Tumorous head with
respect to both chronic control and Wild Type. Analysis of variance
was not applied.
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Figure 8.

Changes in mean plasma thrombocyte count for Tuh,
WT , and Control animals in chronic studies.
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Table 10
Mean Values of Leukocytes for Both Acute and Chronic Assays

ACUTE
Anima l
no.

CONTROL

1
2

-

3
4
5
6

-

CHRONIC

WI~D

TUMQROUS
HEAD

TV E

I

-

I

-

CONTROL

WILD
TYPE

TUMQROUS
HEAD ·

-

-

-

-

-

-

-

-

5,070

7,664

3,263

7,163

8,881

4,786

7
8

6,000

9,034

10,600

13 '185

8,725

9,073

5,717

8,804

6,945

7,655

9,023

12,962

9
10
11

6,646

2,803

4,882

4,577

6,168

9,762

4,788

5,252

9,036

5,785

3,397

11,033

6,413

5,381

6,821

4,704

9,092

-X
s

5,081

6,662

6,685

7,792

7,486

10,168

2,373

2,741

2,510

2,198

2,852

,6 32 ' 106 17, 516 ,666 6,302,277

lr4 ,834 ,839

8,139,119

52

-

-

I

I

6,584

I

-

10 '1 00

9,009

-

7,501

9,509

15 '150
9,926

-

7,344

7,962

9,730

I
I

766.1
586,860

15

Mean values are recorded as leukocytes per cubic millimeter of blood.
T values showed significant increases of both acute and chronic Tumorous head with respect to the Controls and chronic Tumorous head as
compared to chronic Wild Type. Analysis of variance revealed no significance.

44

cute

12

Chronic

11
10

9

8

7.79

7
"'0

....

6

>< 5
u 4
cc

3:

3

2
1

Tu-h
Figure 9.

W-T

Control

Changes in mean leukocyte count for Tuh, Wt,
and Control animals in acute and chronic
studies.
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W-T

Saline

Indurated

11 Normal

1 Normal

2 Purulent

8

1 Normal

1 Purulent

Indurated

11

Tu-h

9

Injection
Sites

No. of
Rabbits

Injection
Types

Norma 1

Normal

11 Normal

9

2 Discolorations

9

2 Discolorations

Spleen

Post-Mortem Inspection

Table 11

11 Normal

9 Normal

2 Discolorations

1 Indurated
modular growth
10 Norma 1

Liver

Gross Inspection

11 Normal

1 Abnormally
red caecum

1 Excessive
pooling in
abdomina 1
cavity

Other

~

U1

Spleen discoloration (spleen
spotted and
dark red areas
Spleen discoloration (spleen
spotted and dark
red areas

Indurated

Indurated

Normal

Normal

Spleen discoloration (spleen
spotted and dark
red areas

Normal

Indurated

Indurated

Indurated

Indurated

4

5

6

Indurated

Purulent

Norma 1

Massive liver
discoloration
(3/4 liver brownish-gray);
abnormally red
caecum

Normal

3

Indurated

Normal

Indurated

Norma 1

Gross Inspection

2

Indurated
growth

Injection
Site

Normal

Gross Inspection

Indurated
growth

Injection
Site

W-T

1

Group

Tu-h

Post-Mortem Inspection

Table 12

Normal

Normal

Normal

Normal

Normal

Normal

Norma 1

Normal

Normal
Normal

Normal

Gross Inspection

Normal

Injection
Site

Saline

+::())

Normal

Normal

Excessive blood
pooling in
abdominal cavity

Normal

Indurated

Indurated

Indurated

7

8

9

10

11

Normal

Spleen abnormally
dark; indurated
nodular growth on
lateral lobe of
liver

Purulent

Group

Gross Inspection

Injection
Site

Tu-h

Normal

Normal

Normal

Indurated

Normal

Normal

Normal

Normal
Normal

Normal

Purulent

Normal

Normal

Nanna 1

Massive liver
discoloration
(3/4 liver brownish-gray)

Normal

Indurated

Normal

Gross Inspection

Normal

Gross Inspection

Injection
Site

Saline

Indurated

Injection
Site

~J- T

Table 12 {continued)

~
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DISCUSSION
The initial laboratory evaluation was designed to determine
the mechanism utilized in reducing the bleeding times reported in
Tuh injected rabbits.

It appeared that these changes could have

been influenced by vascular, platelet, or coagulation anomalies.
Information concerning which processes may be involved were provided
primarily by prothrombin times and platelet counts, although additional tests were performed to provide further information concerning possible coagulation changes or other hematological alterations.

The overall prothrombin times were significantly decreased
from acute to chronically injected animals as shown by analysis of
ariance.

In addition, prothrombin times showed significant reduc-

tions from both acute WT and Tuh groups to chronic WT and Tuh,
respectively {Table 5).

These findings suggest a slight rate change

of the extrinsic and common pathways, that is, Factors V, VII, X,
prothrombin, and fibrinogen (see figure 2).

In general, the clotting

time is shortened as coagulant activity increases, and is detected
by the appearance of fibrin threads.

This relationship is such

that small variations in clotting times represent major differences
in activity when the times are of short duration.

Compared to other

coagulation test systems, the prothrombin test can have a more efficient sensitivity because of its comparatively short time duration.
The significant reduction of prothrombin times from acute WT and Tuh
48

49

to chronic WT and Tuh rabbits does indicate increased overall
activity of the extrinsic system.

When activated prothrombin was

added to plasma, the plasma Factor VII l'eacted with the tissue factor to form a reaction product which possibly accelerated the conversion of Factor X to its activated form, Factor Xa.

This, in turn,

reacted with Factor V, calcium, and tissue phospholipid to form the
extrinsic prothrombin activator that converted the prothrombin to
thrombin.

Thrombin then converted the fibrinogen to fibrin.

The

rate of fibrin formation is dependent on the concentration of the
five extrinsic factors previously mentioned.

This suggests a pos-

sible increased factor concentration in both WT and Tuh injected rabbits probably one or more of the reactions prior to Factor X formation due to their rate limiting nature.

As seen in Table 6, the

significant differences of prothrombin test mean values observed
between both acute and chronic Tuh are greater than those for acute
and chronic WT rabbits.

This greater difference may be caused by

the increased platelet factor concentration in the Tuh group (Table
9).

This factor concentration increase is possibly due to exces-

sive platelet thromboplastic function resulting from the observed
3
thrombocytosis, that is, thrombocyte counts over 400,000/mm (Tables
2 and 9).

The possible acceleratory factors as aforementioned are

platelet factors 1 through 4.

These platelet constituents respec-

tively contribute 1) Factor V through the extrinsic system, 2) a
clotting accelerating protein that further potentiates platelet
aggregation and counteracts the inhibitory antithrombin III, 3) the
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platelet phospholipid which accelerates blood coagulation by participating in reactions involving Factor VIII and Factor V, 4) and the
glycoprotein which further aids in accelerating coagulation (see
pages 6 and 7).

The increase of platelet phospholipid concentration

in particular has the effect of concentrating the various coagulation factors in a localized area, leading to faster reaction rates.
An increase in serotonin released as a result of the high platelet
concentration could have added vasoconstriction effects.
Mean hematocrit values tended to remain about the same, revealing no major changes in blood viscosity.

However, a slight eleva-

tion of the packed cell volume in chronic Tuh groups relative to
acute Tuh groups was noted.

The reason seems to be due to an

increased red cell mass that could be associated with a slightly
higher blood viscosity.
Changes in mean hemoglobin values indicate significant fluctuations between acute and chronic studies within the injected groups.
The hemoglobin concentration in both the chronic WT and Tuh groups
increased significantly over that of their respective acute study
groups.

There was also a significant overall increase in the mean

erythrocyte count in the chronic study as compared to its acute
study.

This may represent a physiologic compensatory response to a

tissue hypoxia indicated by the relatively low hemoglobin concentration in the acute rabbits.

The elevation of erythrocytes appears

to be a facilitated mutual adjustment so as to enhance oxygen
transport, thus elevating the hemoglobin concentration.
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Significant eythrocyte elevation in the chronic Tuh groups is
consistent with the concomitant increase in hemoglobin concentration
in that group.

The erythrocyte content in both Tuh group studies

was significantly greater than the respective WT group studies.

It

has been previously mentioned (page 12) that increased erythrocyte
production is associated with increased thrombocyte production.
Accelerated thrombopoiesis commonly is associated with accelerated
erythropoiesis (49).
There was no significant difference in the hemoglobin concentration between the chronic WT and Tuh rabbits.

However, there was

a significant increase in red blood cell production by the Tuh
injected rabbits.

This rise in erythrocyte count in the chronic Tuh

group was probably due to the proliferation of immature erythrocytes.
The immature cells were probably those during the developmental period at which synthesis of hemoglobin is incomplete.

Erslev and

Gabuzda (60) note that the formation of hemoglobin begins at the
earliest precursor stage of the developing erythroid cell and is
completed when the anucleate reticulocyte matures to an erythrocyte.
Synthesis begins just after the basophilic erythroblast stage.
Leukocyte elevations were significant in both acute and
chronic Tuh groups as compared to their Controls.

These tests

also revealed significant increases of chronic Tuh over chronic WT
groups.

Increases in both WT and Tuh groups are normal responses,

probably due to an increase in the counter antigens.
The data tend to support a reactive thrombocytotic mechanism
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for increased platelet count especially the lack of any observed
prolonged bleeding time (Table 2).

Conclusive evidence of thrombo-

cytosis of the autonomous or reactive nature was not available
because qualitative thrombocyte studies have not been performed.
However, slight increases in erythrocytes and leukocytes, and the
association of the injected tumor element (Table 2 and page 12) all
give added credence to a reactive response.

The homogenates may

possibly accelerate thrombopoiesis which is also associated with
accelerated erythropoiesis suggesting an interrelationship between
erytnropoietic control mechanisms.

Though little is known about the

factors leading to accelerated platelet production in the various
d1sorders associated with accelerated reactive platelet production,
it is established that thrombopoietin does affect the number of
megakar :ocytes found in the bone marrow and their proliferative
behavior.

As previously mentioned, such stimulation increases the

rate of megakaryocyte maturation resulting from an increase in number of mitosis within the individual cells, and possibly an increase
in the size of thrombocytes appearing in circulation.

Thrombocyte

turnover and production rate must be accelerated, yielding a total
thrombocyte mass increase.

Thrombocyte life-span or survival times

usually are not affected by thrombocytosis further suggesting that
the mechanism is over production rather than prolonged life-span.
Post-mortem pathophysiologic analysis (67) revealed the
absence of splenomegaly (Table 2).
was not apparent.

Thromboembolism or hemorrhage

These facts coupled with relatively little
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leukocyte increase, and concomitant increases in erythrocytes were
evident.

All these factors support reactive thrombocytotic tendency

(Table 2).
The more effective occlusion of the trauma site by the
increased number of platelets could be an obvious explanation for
any observed reduction in bleeding time.
Autopsies were performed on 11 animals from each injection
group.

Post-mortem inspections indicated only four spleen discolor-

ations (two Tuh and two WT), two Wt injected rabbit liver discolorations, and irregular indurated and purulent injection sites.

There

appeared to be little or no visual correlation between these discolorations, or the nature of injection sites as compared with abnormal
cell counts or prothrombin times.
from these findings.

Nothing conclusive can be derived

However, pathophysiologic analysis on three

rabDit livers, one from each injection group, revealed aseptic centrilobular hepatolysis in the Tuh rabbit specimen.

Microscopic

analysis showed central necrosis, large zones of hemorrhagic necrosis, and disappearance of cells.

Spleens were normal.

Injection

sites, on biopsy, displayed no apparent abnormal cells (67).
Future investigations should include thrombocyte qualitative
functions such as platelet adhesive tests, platelet aggregation
tests, platelet factor 3 availability tests, and bone marrow aspirations.

These tests will determine if the thrombocytosis is the

reactive or autonomous type.

Acquired qualitative thrombocyte

defects have been described in all the myeloproliferative disorders
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and cannot be ruled

o~t

even though the hemostatic effects of the

thromocytes appear effective.

The basic defect or defects which

underlie the abnormalities in thrombocyte function in the myelopro-

-

liferative syndromes remain to be determined.

While these disorders

have many features in common, the defects may not be identical in
all cases.

These functional defects usually involve aggregation,

adhesion, and/ or secretion dysfunctions.

SUMMARY

The hemostatic mechanism of rabbits appeared to have been
disturbed in response to tumorous-head Drosophila melanogaster
antigens.
The blood coagulation responses of two groups of rabbits, one
group injected with wild-type Drosophila melanogaster and one group
injected with a tumorous-head strain, had somewhat similar reductions in clotting times as compared to a control group.

This indi-

cates that the tumorous-head injected animals do not appear to have
a peculiar accelerated coagulation mechanism as compared with wildtype injected animals.
However, rabbits injected with tumorous-head antigens had a
radical 5-fold elevation in plasma platelet concentration as compared to rabbits injected with the wild-type antigens as well as
control groups.

This aids explanation for a previous speculated

reduction in bleeding time as observed in the tumorous-head
injected rabbits.

The collected hematological data tend to be sup-

portive of a reactive thrombocytosis as compared with an autonomous
reaction.

The precise accelerated thrombokinetic mechanism for the

excessively high increase in platelets remains for future investigations.
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APPENDIX 1
STATISTICAL ANALYSIS
One of the procedures used to analyze the results of the various hematological assays was the unpaired T test.
11

11

The "T test
11

is used in the statistics of small samples with unknown standard
deviations.
t

=X -

The quantity t is given by the equation,

srn

1J

where

x = Sample mean

S = Standard deviation
1..l

n

= Population mean
= Number

That is, t is the deviation of the estimated mean from that of the
population, measured in tenns of s/ ln as the unit.
The unpaired T" test is a derivative of the "T" test and is
11

used when the same individuals are not subjected to each treatment.
In this case, the quantity t is given by the equation,

t

=----

where
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= Mean of lst Group
x2 = Mean of 2nd Group
Sx = Standard error
x1

head
(acute)

Tu~~~ous

Wild-Type

head
(acute)

Tu~~~ous

Control

Sp 2 - 1 · 4083 ( 8 )~~

0045 (8 ) =1.2064

Sp2= 3304(8}~~ 0045(8) =0.6675

Control
vs.
Sp 2 =.3304(8}~~.4083(8) =0. 8694
Wild-Type
(acute)

Pooled Variance

Sxt-x 2 =~.2064(.2222)=.5177

Sx 1 -x 2 =1.6675(.2222}=.3851

Standard Error

T Test Calculations for Prothrombin Times

11

t= 9 ·~~l~j 10

= .3284

t-8.99-9.10 =- 2856
. 3851
.

11

Unpaired T
Distribution

Wild-Type
vs .
Tumorous
head
(Chronic)

Control
vs.
Tumorous
head
(chronic)

Control
vs.
\aJild-Type
(chronic)

Sp 2 =.5559(10~~·4113(10} =0. 4836

Pooled Variance

Standard Error

T Test Calculations for Prothrombin Times (continued)

-

= 1 . 5514

=- . 0567

t-8 .18-7.70 = 1 4384
- • 3337
.

t-8.16-7.70
- .2965

• 3528

t 8.16-8.18

Unpaired 11 T11
Distribution

0
"'
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APPENDIX 2
ANALYSIS OF VARIANCE
Often a researcher
. can use a single experiment advantageously
to study two or more different kinds of treatment.

Analysis of var-

iance rests on a separation of the variance of all the observations
into parts, each of which measures variability attributable to some
specific source.
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Tuh

WT

*denotes significant values

(AB)

Interactions

(B)

Acute = 8.99
Chronic= 8.10
Acute = 9.27
Chronic= 7.97
Acute = 9.10
Chronic= 7.63
0.690

42.656

Acute Mean= 9.12
Chronic Mean= 7.89

Within
Groups

Control

0.296

{A)

Control Mean = 8.52
WT Mean = 8.62
Tuh Mean = 8.37

F Ratio

Between
Groups

.05

Grand Mean = 8.50

-

Ali Animals

I

Analysis of Variance fat Prothrombin Times

0.511

0.000*

0.746

F Values
(significance < .05)

w

0'\

Tuh

WT

*denotes significant values

Interactions
(AB)

(B)

Groups

Acute = 39.88
Chronic= 39.11
Acute = 38.55
Chronic = 38.55
Acute = 38.78
Chronic = 30.78

Acute Mean = 39.10
Chronic Mean = 39.48

\~i thin

Control

Control Mean = 39.50
WT Mean = 38.55
Tuh Mean = 39.78

Between
Groups

(A)

Grand Mean = 39.28

All Animals

2.390

0.580

2.201

- - - - -- -

F Ratio

Analysis of Variance for Hematocrits
- .05

0.115

0.454

0.132

F Values
(significance < .05)

0\
~

Tuh

WT

*denotes significant values

(AB)

Interactions

Acute = 11.25
Chronic = 9.90
Acute = 8.61
Chronic = 9.63
Acute = 9.82
Chronic = 10.77

Acute Mean = 9.89
Chronic Mean = 10.10

Hi thin
Groups

Control

Control Mean = 10.57
WT Mean = 9.12
Tuh Mean = 10.30

Between
Groups
(A)

(B)

Grand Mean = 10.00

_________ ---- ---- -

All Animals

,

4.194

0.305

2.514

F Ratio

0.036*

0.589

0.114

F Values
(significance < .05)

Analysis of Variance fo r Hemoglobin Determination
. = . 05

0'\
01

Tuh

WT

Acute= 5.19
Chronic = 5.79
Acute = 3.62
Chronic = 5.27
Acute = 4.36
Chronic = 6.85

*denotes significant values

Interactions
(AB}

Control
1.443

Acute Mean = 4.39
Chronic Mean = 5.97

thin
Groups

(B)

12.019

Control Mean = 5.49
~JT Mean = 4.44
Tuh Mean = 5.60

Between
Groups
(A)

~Ji

1.439

Grand Mean

F Ratio

for Er·ythrocyte Count

= .05

All Animals

= 5.18

Analysis of Vari anc

0.267

0.003*

0.268

F Values
(significance < .05}

m
m

Tuh

WT

*denotes significant values

Interactions
(AB)

(B)

Acute = 5.80
Chronic= 7.53
Acute = 6.48
Chronic = 6.60
Acute = 6.86
Chronic = 8.72
0.724

3.508

Acute Mean = 6.38
Chronic Mean = 7.62

Within
Groups

Control

0.577

(A)

Control Mean = 6.67
WT Mean = 6.54
Tuh Mean= 7.79

Between
Groups

F Ratio

Grand Mean

All Animals

= 7.00

Analysis of Variance for Leukocytes
= .05

0.501

0.081

0.574

F Values
{signif·cance < .05)
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